1
These results suggest that screening for increased risk of sudden death with ECGs is still problematic. In an accompanying editorial, Washington puts this in a broader con- text, including other reasons why such screening would not be a cost-effective strategy in the United States. He recommends a staged approach that begins with family history, symptoms, and physical examination, with further testing being done based on those results. Nevertheless, we must continue to strive to do better in the prediction of increased risk for sudden death in athletes, whether that is via new screening strategies or improving old ones. Further research will be important. Article page 783< Editorial page 712< Early preterm birth increases mortality in congenital heart disease —Samuel S. Gidding, MD T he morbidity associated with late preterm/early full term delivery in infants with normal hearts is well known. In this issue of The Journal, Cnota et al show that chil- dren born between 34 and 40 weeks gestation have an incremental increase in mortal- ity associated with the degree of prematurity, which is consistent with other work (Pediatrics 2010;126:277-84). The current report supports the importance of waiting as close to term as possible before delivering an infant with in utero diagnosis of congenital heart disease. Too often, the presence of a cardiac defect in the womb cre- ates unnecessary medical anxiety. In most cases, the fetal circulation compensates for the congenital defect. It is only after birth and after the ductus arteriosus closes that emergency intervention is required. The vast majority of babies born with congenital heart disease requires urgent, rather than emergent, care, particularly with the general availability of prostaglandin treatment to maintain ductal patency. Another argument for waiting as close to term as possible is the observation that the brain in certain con- genital heart defects may have delayed development, a potential explanation for the poorer developmental outcome relative to the general population seen in congenital heart disease (Circulation 2010;121:26-33). Although fetal diagnosis probably iden- tifies most serious congenital heart disease in the United States, the benefit on out- comes of this expensive technology has never been demonstrated; earlier delivery may be an unintended adverse consequence. Article page 761< Maternal metabolism, birth weight, and postnatal growth —Stephen R. Daniels, MD, PhD M aternal metabolism, including the maternal lipid profile, may have an impact on fetal growth and longer term outcomes. Most studies of the maternal lipid profile during pregnancy have focused on the third trimester. In this issue of The Journal, Vrijkotte et al report on results of the Amsterdam Born Children and their Develop- ment (ABCD) Study, in which the maternal lipid profile was measured during the first trimester of pregnancy and birth weight and postnatal growth were followed in the infant. The authors found that maternal triglyceride levels, but not total cholesterol levels, were associated with birth weight and a higher prevalence of large for gestational age infants. Lower triglyceride levels in the first trimester were associated with more rapid postnatal growth. Although this is an observational study, the results suggest that triglyceride levels may be a marker for metabolic pathways that influence fetal and postnatal growth. Further research may suggest methods of intervention that could promote optimal fetal growth and, ultimately, postnatal growth. Article page 736< And the glucose was low? —Alan H. Jobe, MD, PhD F or most physiological variables, continuous monitoring will detect abnormal values that would be missed by intermittent or symptom-directed monitoring. It is now possible to continually measure tissue interstitial glucose in infants, but is such monitoring useful in clinical practice? As a research tool, such measurements demonstrate that infants at risk of hypoglycemia often have low glucose values that are not detected clinically. In this issue of The Journal, Harris et al demonstrate that A2 Vol. 159, No. 5

Early preterm birth increases mortality in congenital heart disease

Embed Size (px)

Citation preview

Page 1: Early preterm birth increases mortality in congenital heart disease

A2

These results suggest that screening for increased risk of sudden death with ECGs isstill problematic. In an accompanying editorial,Washington puts this in a broader con-text, including other reasons why such screening would not be a cost-effective strategyin theUnited States. He recommends a staged approach that begins with family history,symptoms, and physical examination, with further testing being done based on thoseresults. Nevertheless, we must continue to strive to do better in the prediction ofincreased risk for sudden death in athletes, whether that is via new screening strategiesor improving old ones. Further research will be important.

Article page 783<Editorial page 712<

Early preterm birthincreases mortality in

congenital heartdisease

—Samuel S. Gidding, MD

The morbidity associated with late preterm/early full term delivery in infants withnormal hearts is well known. In this issue of The Journal, Cnota et al show that chil-

dren born between 34 and 40 weeks gestation have an incremental increase in mortal-ity associated with the degree of prematurity, which is consistent with other work(Pediatrics 2010;126:277-84). The current report supports the importance of waitingas close to term as possible before delivering an infant with in utero diagnosis ofcongenital heart disease. Too often, the presence of a cardiac defect in the womb cre-ates unnecessary medical anxiety. In most cases, the fetal circulation compensates forthe congenital defect. It is only after birth and after the ductus arteriosus closes thatemergency intervention is required. The vast majority of babies born with congenitalheart disease requires urgent, rather than emergent, care, particularly with the generalavailability of prostaglandin treatment to maintain ductal patency. Another argumentfor waiting as close to term as possible is the observation that the brain in certain con-genital heart defects may have delayed development, a potential explanation for thepoorer developmental outcome relative to the general population seen in congenitalheart disease (Circulation 2010;121:26-33). Although fetal diagnosis probably iden-tifies most serious congenital heart disease in the United States, the benefit on out-comes of this expensive technology has never been demonstrated; earlier deliverymay be an unintended adverse consequence.

Article page 761<

Maternal metabolism,birth weight, andpostnatal growth

—Stephen R. Daniels, MD, PhD

Maternal metabolism, including the maternal lipid profile, may have an impact onfetal growth and longer term outcomes. Most studies of the maternal lipid profile

during pregnancy have focused on the third trimester. In this issue of The Journal,Vrijkotte et al report on results of the Amsterdam Born Children and their Develop-ment (ABCD) Study, in which the maternal lipid profile was measured during the firsttrimester of pregnancy and birth weight and postnatal growth were followed in theinfant. The authors found that maternal triglyceride levels, but not total cholesterollevels, were associated with birth weight and a higher prevalence of large for gestationalage infants. Lower triglyceride levels in the first trimester were associated with morerapid postnatal growth.

Although this is an observational study, the results suggest that triglyceride levelsmay be a marker for metabolic pathways that influence fetal and postnatal growth.Further research may suggest methods of intervention that could promote optimalfetal growth and, ultimately, postnatal growth.

Article page 736<

And the glucosewas low?

—Alan H. Jobe, MD, PhD

For most physiological variables, continuous monitoring will detect abnormalvalues that would be missed by intermittent or symptom-directed monitoring. It

is now possible to continually measure tissue interstitial glucose in infants, but issuch monitoring useful in clinical practice? As a research tool, such measurementsdemonstrate that infants at risk of hypoglycemia often have low glucose values thatare not detected clinically. In this issue of The Journal, Harris et al demonstrate that

Vol. 159, No. 5